HR 3618
114th Congress
House
Health
Drug safety, medical device, and laboratory regulation
Drug therapy
Income tax credits
Prescription drugs
User charges and fees
Orphan Drug Fairness Act
Introduced: September 25, 2015
See on congress.gov
Everywhere this bill has been
3 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Oct 2, 2015
Referred to the Subcommittee on Health.
Sep 25, 2015
Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Sep 25, 2015
Introduced in House
Plain-English summary
Orphan Drug Fairness Act
This bill amends the Patient Protection and Affordable Care Act (PPACA) to exclude sales of any drug or biological product approved by the Food and Drug Administration solely for rare diseases or conditions (orphan drug) from the calculation of the annual fee on manufacturers or importers with branded prescription drug sales exceeding $5 million.
This Act is effective as if included in PPACA.
What's happening now
Referred to the Subcommittee on Health.
Committees of jurisdiction
3
Cosponsors
1